Live attenuated hepatitis A vaccines developed in China

Two live, attenuated hepatitis A vaccines, H-2 and LA-1 virus strains, were developed through serial passages of the viruses in cell cultures at 32 degrees C and 35 degrees C respectively. Both vaccines were safe and immunogenic, providing protection against clinical hepatitis A in 95% of the vaccinees, with a single dose by subcutaneous injection. The vaccine recipients were not protected from asymptomatic, subclinical hepatitis A virus (HAV) infection, which induced a similar antibody response as for unvaccinated subjects. A second dose caused anamnestic response and can be used for boosting. Oral immunization of human with H-2 vaccine or of marmoset with LA-1 vaccine failed, and no evidence was found for person-to-person transmission of H-2 strain or for marmoset-to-marmoset transmission of LA-1 strain by close contact. H-2 strain was genetically stable when passaged in marmosets, humans or cell cultures at 37 degrees C; 3 consecutive passages of the virus in marmosets did not cause virulence mutation. The live vaccines offer the benefits of low cost, single dose injection, long - term protection, and increased duration of immunity through subclinical infection. Improved sanitation and administration of 150 million doses of the live vaccines to children had led to a 90% reduction in the annual national incidence rate of hepatitis A in China during the 16-year period, from 1991 to 2006. Hepatitis A (HA) immunization with both live and inactivated HA vaccines was implemented in the national routine childhood immunization program in 2008 and around 92% of the 16 million annual births received the affordable live, attenuated vaccines at 18 months of age. Near elimination of the disease was achieved in a county of China for 14 years following introduction of the H-2 live vaccine into the Expanded Immunization Program (EPI) in 1992.